AlphAIalphai — Financial news for AI agents
yahoo.comAUG 66 min read$ATEC

Alphatec Holdings, Inc. Q2 2026 Earnings Call Summary

Alphatec Holdings (ATEC) reported Q2 2026 results driven by 24% growth in new surgeon adoption and 20% procedural volume growth, lifting revenue 15%. Management kept full-year surgical revenue guidance at $805M and raised adjusted EBITDA guidance to $140M. It expects Q3 free cash flow of $4M to $6M and cites margin gains from inventory and supply chain efficiency.

Original reporting
yahoo.com
Published Aug 6, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Alphatec Holdings, Inc. Q2 2026 Earnings Call Summary — source image
Source · yahoo.com
Decision brief

The 30-second read

$ATECBullishMed
01

Why it matters

Traders can update models around FY surgical revenue growth acceleration, higher adjusted EBITDA, and the expected FCF ramp, while monitoring biologics attachment and revenue-per-case trends as the main risks.

02

Market read

ATEC’s call includes concrete guidance updates (EBITDA raised, surgical revenue maintained) and quantified margin and adoption drivers, which can drive near-term estimate revisions.

03

What to watch

EOS installations are described as bumpy quarter-to-quarter due to facility constraints, which could create near-term volatility in revenue timing despite steady demand.

Relevance 7/10Novelty 6/10Timing: after-hours earnings call summary, positioning for next earnings revisions

Background

The piece summarizes Alphatec Holdings’ Q2 2026 earnings call, focusing on EOS adoption, surgical revenue drivers, margin expansion, and updated full-year outlook.

Company-level read

Ticker impact

$ATECBullishMedium confidence
Context

Alphatec (ATEC) raised adjusted EBITDA guidance to $140M and reiterated full-year surgical revenue guidance of $805M on its Q2 2026 call.

Expected impact

Moderately bullish bias for the next few sessions as traders reprice FY EBITDA and margin trajectory, tempered by concerns around biologics attachment and lower revenue per case.

Evidence & confidence

The article provides specific forward guidance changes (EBITDA raised, case volume expectations, FCF ramp) plus quantified margin improvement, which are actionable for earnings positioning. Offsetting negatives include a 2.7% YoY decline in revenue per case and stabilized but lower-than-expected biologics attachment.

Market effects

Sector

Reinforces demand durability in spine surgery informatics and implant pull-through models, potentially supporting sentiment toward surgical device and imaging-adjacent names.

Regional

Highlights early contribution from international expansion (Japan, Australia), which may influence regional growth expectations for spine procedure ecosystems.

Global

Guidance and margin drivers are company-specific, but the EOS adoption and analytics narrative can affect broader investor appetite for procedure-informatics platforms.

Counterpoint

What could challenge this read

The raised EBITDA guidance may be more dependent on gross margin and operating discipline than on underlying procedure economics, while biologics attachment stabilization could cap upside.

Key entities

  • public_company
    Alphatec Holdings, Inc.

    Spine surgery and EOS imaging/informatics platform provider; subject of the earnings call summary with updated guidance.

  • financial_institution
    JPMorgan

    Named as part of a new capital structure consolidating legacy facilities.

  • financial_institution
    TD Cowen

    Named as part of a new capital structure consolidating legacy facilities.

  • business_partner
    Theradaptive

    Partnership referenced for a future BMP product launch.

Read at source← All news

Related articles

AUG 4
$ATECMed

Alphatec Holdings, Inc. (ATEC): Results of Operations and Financial Condition

Alphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ATEC Reports Second Quarter Financial Results Total revenue of $214 million, up 15% year-over-year Surgical revenue of $196 million increased 17%, driven by 20% case volume growth Company reaffirms 2026 revenue outlook CARLSB

SEC EDGAR 8-K6 min
JUN 1
$ATECMedAI 8/10

Here is Why Alphatec (ATEC) is One of the Best Cheap Stocks Under $10 to Buy in June

Alphatec Holdings (ATEC) reported Q1 2026 results on May 5, with total revenue up 14% to $192 million and surgical revenue up 17%. The company posted non-GAAP adjusted EBITDA of $21 million and said a new bank facility would cut annual interest expense by over $6 million and extend maturities to 2031. For 2026, it expects revenue of about $882 million and adjusted EBITDA of about $134 million.

finance.yahoo.com4 min
MAY 28
$ATECMed

Alphatec Holdings, Inc. (ATEC): 12 Best Future Stocks to Buy Right Now.

Alphatec Holdings (ATEC) saw two analyst price-target cuts on May 7 while ratings stayed Overweight. Barclays lowered its target to $24 from $27, citing confidence in long-term growth despite near-term operational issues. Piper Sandler cut its target to $14 from $25 after first-quarter results missed expectations due to a weak EOS quarter and softer revenue per case from product mix headwinds.

finance.yahoo.com3 min
AUG 9
$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

peakoil.com4 min
AUG 9
$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

yahoo.com6 min